Zhengye Biotechnology Holding Ltd
ZYBT evidence brief
What we can confirm
- Market Cap:
- $73.5M
What it means
What to watch
Prepared research question
What matters most for ZYBT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZYBT
Zhengye Biotechnology Holding Ltd (ZYBT) is a China-based animal vaccine developer focused on swine and household animal vaccines, with recent regulatory approvals and ongoing international expansion.
Key risk: Swine vaccine demand risk
Market Cap
$73.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Zhengye Biotechnology Holding Ltd (ZYBT) is a China-based animal vaccine developer focused on swine and household animal vaccines, with recent regulatory approvals and ongoing international expansion.
- Obtained a Registration Certificate of New Veterinary Drugs for the Mycoplasma Bovis Live Vaccine (HB150 strain) on February 25, 2025, and a production approval number on July 23, 2025 [sec · filed 2026-04-28].
- Shareholders' equity was $35.7M as of 2025-12-31 [sec].
- Cash and cash equivalents were RMB51.7 million (US$7.2 million) as of December 31, 2025 [sec · filed 2026-04-28].
- Expanding into overseas markets including Egypt, Pakistan, Vietnam, and planning entry into Africa, Central Asia, and West Asia [sec · filed 2026-04-28].
- Established a new domestic subsidiary, Beijing Zhongnong Zhengye Biotechnology Co., Ltd., to integrate sales, technical services, and marketing [sec · filed 2026-04-28].
What works
- Recent regulatory approvals for a new veterinary vaccine (Mycoplasma Bovis Live Vaccine) demonstrate product development progress [sec · filed 2026-04-28].
- International expansion into multiple overseas markets (Egypt, Pakistan, Vietnam, and planned Africa/Central Asia/West Asia) diversifies revenue sources [sec · filed 2026-04-28].
- Management believes available cash and forecasted net cash flows are sufficient to meet obligations for at least one year after the financial statement issuance date [sec · filed 2026-04-28].
What to weigh
- The company's business is heavily dependent on swine vaccines, and any reduction in demand for swine vaccines could adversely affect its financial condition [sec · filed 2026-04-28].
- Many pipeline products are in early development stages and require significant additional development, clinical testing, and regulatory approvals before commercialization [sec · filed 2026-04-28].
- The company relies on collaborative partners, licensees, and third parties for research, development, and commercialization; failure of these partners could materially harm its business [sec · filed 2026-04-28].
- Historical growth rates may not be sustainable, and the company cannot guarantee maintaining past growth performance [sec · filed 2026-04-28].
From the filings
Quoted directly from source documents.
Recent regulatory approval for a new veterinary vaccine
“the operating entity obtained a Registration Certificate of New Veterinary Drugs for the Mycoplasma Bovis Live Vaccine (HB150 strain) on February 25, 2025, and received a production approval number on July 23, 2025”
SEC filings · April 28, 2026
Dependence on swine vaccine demand
“any reduction in demand of swine vaccines could have an adverse effect on our business, financial condition, results of operations, cash flows, and prospects”
SEC filings · April 28, 2026
Risks & what to watch (4)›
Key risks
- Swine vaccine demand risk — Reduction in swine vaccine demand could materially harm business and financial condition [sec · filed 2026-04-28].
- Clinical trial and regulatory delays — Products require costly, time-consuming trials and approvals; delays could diminish competitive advantages or revenue [sec · filed 2026-04-28].
- Dependence on third-party partners — Business relies on collaborators, licensees, and third parties; their failure to perform could materially harm operations [sec · filed 2026-04-28].
- Unsustainable growth rate — Historical growth rates may not be sustainable; no guarantee of maintaining past performance [sec · filed 2026-04-28].
What to watch
- Progress of the Pentavalent Inactivated Vaccine for C and other pipeline products through clinical trials and regulatory approvals [sec · filed 2026-04-28].
- Revenue and market adoption of the newly approved Mycoplasma Bovis Live Vaccine [sec · filed 2026-04-28].
- Expansion into new overseas markets (Africa, Central Asia, West Asia) and its impact on revenue diversification [sec · filed 2026-04-28].
- Ability to maintain cash runway and manage working capital given reliance on bank loans and customer advances [sec · filed 2026-04-28].
Sources: SEC filings · Generated September 10, 2026 · How we verify sources →
Run Zhengye Biotechnology Holding Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zhengye Biotechnology Holding Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of Apr 21, 2026- % of float
- 3.3%
- Days to cover
- 0.3
- Shares short
- 147,787
- Daily short volume (Jul 17, 2026)
- 1.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZYBT short interestFrequently asked questions
What is the AI investment thesis for Zhengye Biotechnology Holding Ltd?
Zhengye Biotechnology Holding Ltd (ZYBT) is a China-based animal vaccine developer focused on swine and household animal vaccines, with recent regulatory approvals and ongoing international expansion.
Who is the CEO of Zhengye Biotechnology Holding Ltd?
Mr. Songlin Song is the chief executive officer of Zhengye Biotechnology Holding Ltd (ZYBT).
Where is Zhengye Biotechnology Holding Ltd headquartered?
Zhengye Biotechnology Holding Ltd (ZYBT) is headquartered in Jilin, China.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.